Compare BridgeBio Pharma Inc (BBIO) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Teladoc Health Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Teladoc Health Inc trades at $9.3 (market cap $1.67B). The key difference: BridgeBio Pharma Inc is far larger — about 9.9× Teladoc Health Inc's market cap. Which is the better fit depends on your goals.
| BBIO | TDOC | |
|---|---|---|
Market Cap | $16.46B | $1.67B |
Sector | Health | Health |
52-Week High | $90.17 | $9.65 |
52-Week Low | $44.81 | $4.47 |
Enterprise Value | $18.02B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TDOC trades at $9.65, up 3.99% with bullish technical signals but mixed fundamentals. Revenue remains stable around $2.5B, yet net losses persist with a -6.81% margin. Analyst consensus is cautious with 64% hold ratings, though recent partnerships like Walmart's Better Care show growth potential. Cash flow trends indicate significant net outflows, raising liquidity concerns despite a solid gross margin of 69.29%.
Outlook hinges on cost management and partnership execution; risks include sustained losses and high debt. The stock offers speculative upside if profitability improves, but investor patience is required amid competitive pressures and volatile sentiment. Current price near resistance at $10 suggests limited near-term upside without positive earnings surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
